Advanced search
Publication Cover
Expert Review of Anticancer Therapy Volume 24, 2024 - Issue 8
Submit an article Journal homepage
101
Views
0
CrossRef citations to date
0
Altmetric
Meeting Report

2024 ASCO genitourinary cancers symposium: a focus on renal cell carcinoma

Viria Becciaa Medical Oncology, Department of Translational Medicine and Surgery, Catholic University of the Sacred Heart, Rome, ItalyView further author information
,
Daniela Arduinia Medical Oncology, Department of Translational Medicine and Surgery, Catholic University of the Sacred Heart, Rome, ItalyView further author information
,
Roberto Iacovellia Medical Oncology, Department of Translational Medicine and Surgery, Catholic University of the Sacred Heart, Rome, Italy;b Medical Oncology, Department of Medical and Surgical Sciences, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, ItalyCorrespondence[email protected]
View further author information
,
Alessandro Scalaa Medical Oncology, Department of Translational Medicine and Surgery, Catholic University of the Sacred Heart, Rome, ItalyView further author information
,
Denis Occhipintia Medical Oncology, Department of Translational Medicine and Surgery, Catholic University of the Sacred Heart, Rome, ItalyView further author information
,
Chiara Ligatoa Medical Oncology, Department of Translational Medicine and Surgery, Catholic University of the Sacred Heart, Rome, ItalyView further author information
,
Luigi Rocaa Medical Oncology, Department of Translational Medicine and Surgery, Catholic University of the Sacred Heart, Rome, ItalyView further author information
,
Pierluigi Russoc Department of Urology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, ItalyView further author information
,
Nazario Foschic Department of Urology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, ItalyView further author information
,
Giampaolo Tortoraa Medical Oncology, Department of Translational Medicine and Surgery, Catholic University of the Sacred Heart, Rome, Italy;b Medical Oncology, Department of Medical and Surgical Sciences, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, ItalyView further author information
&
Chiara Ciccareseb Medical Oncology, Department of Medical and Surgical Sciences, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, ItalyView further author information
 show all
Pages 657-660 | Received 16 Feb 2024, Accepted 17 Jun 2024, Published online: 27 Jun 2024

References

  • Motzer RJ, Ravaud A, Patard JJ, et al. Adjuvant sunitinib for high-risk renal cell carcinoma after nephrectomy: subgroup analyses and updated overall survival results. Eur Urol. 2018 Jan [cited 2017 Sep 28];73(1):62–68. doi: 10.1016/j.eururo.2017.09.008
  • Ciccarese C, Strusi A, Arduini D, et al. Post nephrectomy management of localized renal cell carcinoma. From risk stratification to therapeutic evidence in an evolving clinical scenario. Cancer Treat Rev. 2023 Apr [cited 2023 Feb 24];115:102528. doi: 10.1016/j.ctrv.2023.102528
  • Choueiri Toni K, Tomczak P, Park SH, et al. Overall survival results from the phase 3 KEYNOTE-564 study of adjuvant pembrolizumab versus placebo for the treatment of clear cell renal cell carcinoma (ccRCC). J Clin Oncol 42. 2024. (suppl 4; abstr LBA359). doi: 10.1200/JCO.2024.42.4_suppl.LBA359
  • Motzer RJ, Russo P, Grünwald V, et al. Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial. Lancet. [cited 2023 Mar 11. cited 2023 Mar 11];401(10379):821–832. doi: 10.1016/S0140-6736(22)02574-0
  • Motzer RJ, Bex A, Russo P, et al. Adjuvant nivolumab monotherapy vs placebo for localized renal cell carcinoma at high risk of relapse after nephrectomy: results from part B of the randomized, phase 3 CheckMate 914 trial. J Clin Oncol. 2024;42(4_suppl):358–358. doi: 10.1200/JCO.2024.42.4_suppl.LBA358
  • Pal SK, Uzzo R, Karam JA, et al. Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial. Lancet. [cited 2022 Oct 1. cited 2022 Oct 1];400(10358):1103–1116. doi: 10.1016/S0140-6736(22)01658-0
  • Labaki C, Choueiri TK. Perioperative immunotherapy for renal cell carcinoma: looking beyond the data. Nat Rev Clin Oncol. 2023;20(2):65–66. doi: 10.1038/s41571-022-00710-5
  • Fessas P, Lee H, Ikemizu S, et al. A molecular and preclinical comparison of the PD-1-targeted T-cell checkpoint inhibitors nivolumab and pembrolizumab. Semin Oncol. 2017 Apr [cited 2017 Jul 4];44(2):136–140. doi: 10.1053/j.seminoncol.2017.06.002
  • Tannir NM, Escudier B, McDermott DF, et al. Nivolumab plus ipilimumab (NIVO+IPI) vs sunitinib (SUN) for first-line treatment of advanced renal cell carcinoma (aRCC): long-term follow-up data from the phase 3 CheckMate 214 trial. J Clin Oncol. 2024;42(4_suppl):363–363. doi: 10.1200/JCO.2024.42.4_suppl.363
  • Bourlon MT, Escudier B, Burotto M, et al.Nivolumab plus cabozantinib (N+C) vs sunitinib (S) for previously untreated advanced renal cell carcinoma (aRCC): results from 55-month follow-up of the CheckMate 9ER trial. J Clin Oncol. 2024;42(4_suppl):362–362. doi: 10.1200/JCO.2024.42.4_suppl.362
  • Tan AR, Im SA, Mattar A, et al. Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDerica): a randomised, open-label, multicentre, non-inferiority, phase 3 study. Lancet Oncol. 2021 Jan;22(1):85–97. doi: 10.1016/S1470-2045(20)30536-2 Epub 2020 Dec 21. Erratum in: Lancet Oncol. 2021 Feb;22(2):e42.
  • George S, Bourlon MT, Chacon MR, et al. Subcutaneous nivolumab (NIVO SC) vs intravenous nivolumab (NIVO IV) in patients with previously treated advanced or metastatic clear cell renal cell carcinoma (ccRCC): pharmacokinetics (PK), efficacy, and safety results from CheckMate 67T. J Clin Oncol. 2024;42(4_suppl):360–360. doi: 10.1200/JCO.2024.42.4_suppl.LBA360
  • Pal SK, Albiges L, Tomczak P, et al. Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial. Lancet. [Updated 2023 Jul 15. cited 2023 Jul 15];402(10397):185–195. doi: 10.1016/S0140-6736(23)00922-4
  • Ciccarese C, Iacovelli R, Porta C, et al. Efficacy of VEGFR-TKIs plus immune checkpoint inhibitors in metastatic renal cell carcinoma patients with favorable IMDC prognosis. Cancer Treat Rev. 2021 Nov [cited 2021 Sep 20];100:102295. doi: 10.1016/j.ctrv.2021.102295

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.